Search

everythinglearnresearchcommunity

for

Search:↓

Women with early-onset baldness should be checked for early bone loss, but bone density doesn't change with baldness severity.

Cells from balding scalps have more androgen receptors than cells from non-balding scalps.

High levels of testosterone and 5α-DHT can lead to cell death in cells important for hair growth.

Scientists created cell lines from balding patients and found that cells from the front of the scalp are more affected by hormones that cause hair loss than those from the back.

Male-pattern baldness might be caused by the effect of hormones on scalp blood vessels.

Higher urethral PSA levels after prostate removal may be linked to more scalp hair loss and more PSA in urethral glands.

A substance called DKK-1 increases in balding areas and causes hair cells to die when exposed to DHT.

Androgenetic alopecia is a common hair loss condition caused by testosterone effects on hair follicles, leading to thinner, shorter, and less pigmented hair, diagnosed using scalp dermoscopy and treated with topical minoxidil, antiandrogen agents, and 5-alpha reductase inhibitors.

The document concludes that hair loss is common and can be treated with medications like minoxidil or surgical options, and it significantly affects people's psychological well-being.

Androgens can both promote and prevent hair growth due to differences in gene expression in hair follicles.

cp-asiAR may effectively treat hair loss by targeting androgen receptors.

IGFBP-rP1 could be a new treatment for a common type of hair loss.

Changing hair follicle identity could potentially reverse balding.

cp-asiAR may effectively treat androgenetic alopecia by promoting hair growth and reducing androgen receptor activity.

Finasteride reduces hair follicle cell death in androgenetic alopecia.

The enzyme that changes testosterone to a stronger form is mostly found in the part of the hair follicle called the dermal papilla.

The conclusion is that a treatment called cp-asiAR can reduce hair loss and promote hair growth, making it a potential new therapy for androgenetic alopecia.

UV light might cause excessive hair growth by increasing PGE2 in the skin.

Botulinum toxin may help treat male pattern baldness.

Androgenetic alopecia, a genetic disorder affecting up to 50% of adults, is caused by an excessive response to androgens leading to hair follicle shrinkage. Treatments include FDA-approved drugs, other therapies like low-dose oral minoxidil, and hair transplantation.

Androgenic alopecia causes hair thinning, and treatments include minoxidil, finasteride, and light therapy.

Early-stage male pattern baldness shows two types of hair loss: one on the top of the head linked to hormonal changes, and another at the back of the head. The top hair loss responds well to specific treatment, while the back hair loss does not.

Finasteride and minoxidil are effective for hair loss, but continued research is needed for better treatments.

Hirsute women have lower type 2 17β-HSD enzyme levels, which improve with treatment.

Hormone therapy with estradiol and spironolactone can regrow scalp hair in transgender women by lowering testosterone to female levels.

High aldosterone and free testosterone levels link to female hair loss; testing aldosterone may predict hypertension risk.

Menopausal women have higher androgen levels, which can cause symptoms like facial hair growth and low sexual desire.

Higher DKK-1 levels found in hair loss patients; L-ascorbic acid 2-phosphate, L-threonate, and ginsenoside F2 may help promote hair growth.

The effects of estrogen on human scalp hair growth are unclear and need more research.

Testosterone metabolism in balding scalp cells may not be the main cause of hair loss.